EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Evaluation of Homologous Recombination Deficiency in Ovarian Cancer

Rubina Ratnaparkhi, Melissa Javellana, Andrea Jewell, Lori Spoozak

Current Treatment Options in Oncology · 2024-02 · 25 (2) · 237-260

DOI: 10.1007/s11864-024-01176-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 01.02.2024. Verfasst von Rubina Ratnaparkhi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS, USA. rratnaparkhi@ku…. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 109 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: Homologous recombination deficiency (HRD) is an important biomarker guiding selection of ovarian cancer patients who will derive the most benefit from poly(ADP-ribose) polymerase inhibitors (PARPi). HRD prevents cells from repairing double-stranded DNA damage with high fidelity, PARPis limit single-stranded repair, and together these deficits induce synthetic lethality. Germline or somatic BRCA mutations represent the narrowest definition of HRD, but do not reflect all patients who will have a durable PARPi response. HRD can also be defined by its downstream consequences, which are measured by different metrics depending on the test used. Ideally, all patients will undergo genetic counseling and germline testing shortly after diagnosis and have somatic testing sent once an adequate tumor sample is available. Should barriers to one test be higher, pursuing germline testing with reflex to somatic testing for BRCA wildtype patients or somatic testing first strategies are both evidence-based. Ultimately both tests offer complementary information, germline testing should be pursued for any patient with a history of ovarian cancer, and somatic testing is valuable at recurrence if not performed in the upfront setting. There is a paucity of data to suggest superiority of one germline or somatic assay; therefore, selection should optimize turnaround time, cost to patients, preferred result format, and logistical burden. Each clinic should implement a standard testing strategy for all ovarian cancer patients that ensures HRD status is known at the time of upfront chemotherapy completion to facilitate comprehensive counseling about anticipated maintenance PARPi benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsHumansFemalePoly(ADP-ribose) Polymerase InhibitorsSynthetic Lethal MutationsHomologous Recombination

Stichwörter der Autor:innen

Genes, BRCA1*Genes, BRCA2*GermlineHomologous recombination deficiencyOvarian cancerPoly(ADP-ribose) polymerase inhibitorsSomatic

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS, USA. rratnaparkhi@kumc.edu.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS, USA.

Zitieren

APA

Ratnaparkhi, R., Javellana, M., Jewell, A., & Spoozak, L. (2024). Evaluation of Homologous Recombination Deficiency in Ovarian Cancer. Current Treatment Options in Oncology, 25(2), 237-260. https://doi.org/10.1007/s11864-024-01176-6

Vancouver

Ratnaparkhi R, Javellana M, Jewell A, Spoozak L. Evaluation of Homologous Recombination Deficiency in Ovarian Cancer. Current Treatment Options in Oncology. 2024;25(2):237-260. doi:10.1007/s11864-024-01176-6

BibTeX
@article{Ratnaparkhi2024,
  author = {Ratnaparkhi, Rubina and Javellana, Melissa and Jewell, Andrea and Spoozak, Lori},
  title = {Evaluation of Homologous Recombination Deficiency in Ovarian Cancer},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  volume = {25},
  number = {2},
  pages = {237--260},
  doi = {10.1007/s11864-024-01176-6}
}
Kostenlos starten →